November 9, 2017 QUARTERLY REPORT – 2017 Q3
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 3Q 2017...
August 31, 2017 QUARTERLY REPORT – 2017 Q2
Posted at 10:00h
in Uncategorized
Q2 2017 Quarterly report Vaccibody...
June 21, 2017 Vaccibody announces positive results from the 12-month analysis of the phase I part of the clinical trial VB C-01 in patients with high-grade cervical dysplasia
Posted at 10:00h
in Uncategorized
Vaccibody AS today announced positive results from the phase I part of the clinical trial VB C-01. This trial is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by...
May 10, 2017 QUARTERLY REPORT – 2017 Q1
Posted at 12:00h
in quarterly-reports
Q1 17 Quarterly report Vaccibody...
March 23, 2017 Vaccibody AS announces vaccination of first patient in its phase IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Posted at 10:00h
in Uncategorized
Vaccibody AS announced today vaccination of the first patient in its phase IIa study – an exploratory, open-label, multicenter study with VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). The phase I part of...
March 2, 2017 QUARTERLY REPORT – 2016 Q4
Posted at 18:14h
in quarterly-reports
Q416 Quarterly report Vaccibody...
March 2, 2017 Vaccibody AS announces approval of amendment of IMPD allowing to start of expansion phase in its phase I/IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Posted at 18:03h
in Uncategorized
Vaccibody AS announces today that inclusion of patients in the expansion phase (phase IIa) of its multicentre trial VB C-01 can be initiated as the company was informed by Paul-Ehrlich Institut („PEI“), the German regulatory authorities, that an amendment to the IMPD (Investigational Medicinal Product...